B. Schoser Et Al. , "Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial," NEUROMUSCULAR DISORDERS , vol.32, 2022
Schoser, B. Et Al. 2022. Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial. NEUROMUSCULAR DISORDERS , vol.32 .
Schoser, B., Kishnani, P., Kushlaf, H., Ladha, S., Mozaffar, T., Straub, V., ... Toscano, A.(2022). Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial. NEUROMUSCULAR DISORDERS , vol.32.
Schoser, B. Et Al. "Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial," NEUROMUSCULAR DISORDERS , vol.32, 2022
Schoser, B. Et Al. "Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial." NEUROMUSCULAR DISORDERS , vol.32, 2022
Schoser, B. Et Al. (2022) . "Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial." NEUROMUSCULAR DISORDERS , vol.32.
@article{article, author={B. Schoser Et Al. }, title={Efficacy and safety of Avalglucosidase Alfa in participants with late-onset Pompe Disease after 145 weeks' treatment during the COMET trial}, journal={NEUROMUSCULAR DISORDERS}, year=2022}